{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:02:49Z","timestamp":1772146969025,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Sharjah Targeted Grant","award":["2301110392"],"award-info":[{"award-number":["2301110392"]}]},{"name":"Tour De Cure Research Grant","award":["RSP-117-FY2023"],"award-info":[{"award-number":["RSP-117-FY2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37464-4","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:14:52Z","timestamp":1770434092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials"],"prefix":"10.1038","volume":"16","author":[{"given":"Ahmad Y.","family":"Abuhelwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humaid O.","family":"Al-Shamsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Abuhelwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A. Y.","family":"Alqudah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Bustanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad H","family":"Semreen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karem H","family":"Alzoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natansh D","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"2","key":"37464_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bcp.15499","volume":"89","author":"Z Al-Yafeai","year":"2023","unstructured":"Al-Yafeai, Z., Ghoweba, M., Ananthaneni, A., Abduljabar, H. & Aziz, D. Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study. Br. J. Clin. Pharmacol. 89 (2), 641\u2013648 (2023).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"37464_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11936-018-0618-y","volume":"20","author":"DH Lee","year":"2018","unstructured":"Lee, D. H. & Fradley, M. G. Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention. Curr. Treat. Options Cardiovasc. Med. 20, 1\u201314 (2018).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"issue":"22","key":"37464_CR3","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","volume":"107","author":"MF Oliveira","year":"2021","unstructured":"Oliveira, M. F. et al. Optimising cardiovascular care of patients with multiple myeloma. Heart 107 (22), 1774\u20131782 (2021).","journal-title":"Heart"},{"issue":"11","key":"37464_CR4","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00277-022-04959-9","volume":"101","author":"I Toppila","year":"2022","unstructured":"Toppila, I. et al. Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005\u20132016. Ann. Hematol. 101 (11), 2485\u20132495 (2022).","journal-title":"Ann. Hematol."},{"key":"37464_CR5","doi-asserted-by":"publisher","first-page":"204062072210867","DOI":"10.1177\/20406207221086755","volume":"13","author":"X Yin","year":"2022","unstructured":"Yin, X., Fan, F., Zhang, B., Hu, Y. & Sun, C. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Therapeutic Adv. Hematol. 13, 20406207221086755 (2022).","journal-title":"Therapeutic Adv. Hematol."},{"issue":"8","key":"37464_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/ph15081007","volume":"15","author":"AS Perpinia","year":"2022","unstructured":"Perpinia, A. S. et al. Pharmaceutical prevention and management of cardiotoxicity in hematological malignancies. Pharmaceuticals 15 (8), 1007 (2022).","journal-title":"Pharmaceuticals"},{"issue":"14","key":"37464_CR7","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1182\/bloodadvances.2024015287","volume":"9","author":"AY Abuhelwa","year":"2025","unstructured":"Abuhelwa, A. Y. et al. Statin use and survival in CLL\/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials. Blood Adv. 9 (14), 3566\u20133575 (2025).","journal-title":"Blood Adv."},{"key":"37464_CR8","doi-asserted-by":"crossref","unstructured":"Al-Kindi, S. G. & Oliveira, G. H. (eds) Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clinic Proceedings; : Elsevier. (2016).","DOI":"10.1016\/j.mayocp.2015.09.009"},{"issue":"9","key":"37464_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"S Bringhen","year":"2018","unstructured":"Bringhen, S. et al. Cardiovascular adverse events in modern myeloma therapy\u2013incidence and risks. A review from the European myeloma network (EMN) and Italian society of arterial hypertension (SIIA). Haematologica 103 (9), 1422 (2018).","journal-title":"Haematologica"},{"issue":"3","key":"37464_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer, C., Driessen, C., Szabo, Z. & Mateos, M-V. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 9 (3), 26 (2019).","journal-title":"Blood Cancer J."},{"issue":"2","key":"37464_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","volume":"17","author":"KD Kistler","year":"2017","unstructured":"Kistler, K. D. et al. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study. Clin. Lymphoma Myeloma Leuk. 17 (2), 89\u201396 (2017). e3.","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"37464_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus Lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11 (1), 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"issue":"1","key":"37464_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40959-023-00159-0","volume":"9","author":"A Mir","year":"2023","unstructured":"Mir, A. et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardio-Oncology 9 (1), 10 (2023).","journal-title":"Cardio-Oncology"},{"key":"37464_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00432-012-1331-y","volume":"139","author":"I Kozanoglu","year":"2013","unstructured":"Kozanoglu, I. et al. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. J. Cancer Res. Clin. Oncol. 139, 327\u2013335 (2013).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"21","key":"37464_CR15","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1158\/1078-0432.CCR-17-0678","volume":"23","author":"EA Rojas","year":"2017","unstructured":"Rojas, E. A. et al. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma. Clin. Cancer Res. 23 (21), 6602\u20136615 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"37464_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajh.24582","volume":"92","author":"YL Hwa","year":"2017","unstructured":"Hwa, Y. L. et al. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. Am. J. Hematol. 92 (1), 50\u201355 (2017).","journal-title":"Am. J. Hematol."},{"issue":"33","key":"37464_CR17","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","volume":"34","author":"KM Sanfilippo","year":"2016","unstructured":"Sanfilippo, K. M. et al. Statins are associated with reduced mortality in multiple myeloma. J. Clin. Oncol. 34 (33), 4008 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"37464_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ajh.25778","volume":"95","author":"E Br\u00e5nvall","year":"2020","unstructured":"Br\u00e5nvall, E. et al. Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. Am. J. Hematol. 95 (6), 652\u2013661 (2020).","journal-title":"Am. J. Hematol."},{"issue":"7","key":"37464_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.thj.6200571","volume":"5","author":"T Buchler","year":"2005","unstructured":"Buchler, T. et al. Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. Hematol. J. 5 (7), 559\u2013564 (2005).","journal-title":"Hematol. J."},{"issue":"11","key":"37464_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Daratumumab, Lenalidomide, and dexamethasone versus Lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 22 (11), 1582\u20131596 (2021).","journal-title":"Lancet Oncol."},{"issue":"14","key":"37464_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375 (14), 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"37464_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375 (8), 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"37464_CR23","unstructured":"Harrell, F. E. Jr Hmisc: Harrell Miscellaneous. (2022)."},{"issue":"4","key":"37464_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","volume":"12","author":"SJ Grant","year":"2021","unstructured":"Grant, S. J. et al. Transplant-ineligible newly diagnosed multiple myeloma: current and future approaches to clinical care: A young international society of geriatric oncology review paper. J. Geriatric Oncol. 12 (4), 499\u2013507 (2021).","journal-title":"J. Geriatric Oncol."},{"issue":"9","key":"37464_CR25","first-page":"CD014739","volume":"9","author":"LA Kahale","year":"2021","unstructured":"Kahale, L. A. et al. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving Immunomodulatory agents. Cochrane Database Syst. Rev. 9 (9), CD014739 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"37464_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ejh.13559","volume":"106","author":"YL Hwa","year":"2021","unstructured":"Hwa, Y. L. et al. Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with Pomalidomide. Eur. J. Haematol. 106 (3), 433\u2013436 (2021).","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"37464_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/1078-0432.CCR-05-1698","volume":"12","author":"AK Sood","year":"2006","unstructured":"Sood, A. K. et al. Stress hormone\u2013mediated invasion of ovarian cancer cells. Clin. Cancer Res. 12 (2), 369\u2013375 (2006).","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"37464_CR28","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","volume":"70","author":"EK Sloan","year":"2010","unstructured":"Sloan, E. K. et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70 (18), 7042\u20137052 (2010).","journal-title":"Cancer Res."},{"issue":"7","key":"37464_CR29","first-page":"2866","volume":"61","author":"K Masur","year":"2001","unstructured":"Masur, K., Niggemann, B., Zanker, K. S. & Entschladen, F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by \u03b2-blockers. Cancer Res. 61 (7), 2866\u20132869 (2001).","journal-title":"Cancer Res."},{"issue":"9","key":"37464_CR30","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/carcin\/10.9.1753","volume":"10","author":"HM Schuller","year":"1989","unstructured":"Schuller, H. M. & Cole, B. Regulation of cell proliferation by \u03b2-adrenergjc receptors in a human lung adenocarcinoma cell line. Carcinogenesis 10 (9), 1753\u20131755 (1989).","journal-title":"Carcinogenesis"},{"issue":"1","key":"37464_CR31","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ygyno.2012.07.059","volume":"127","author":"R Eskander","year":"2012","unstructured":"Eskander, R. et al. Beta blocker use and ovarian cancer survival: a retrospective cohort study. Gynecol. Oncol. 127 (1), S21 (2012).","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"37464_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ygyno.2013.03.007","volume":"129","author":"F Heitz","year":"2013","unstructured":"Heitz, F. et al. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer\u2014a combined analysis of 2 prospective multicenter trials by the AGO study Group, NCIC-CTG and EORTC-GCG. Gynecol. Oncol. 129 (3), 463\u2013466 (2013).","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"37464_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.canep.2014.03.011","volume":"38","author":"CR Cardwell","year":"2014","unstructured":"Cardwell, C. R., Coleman, H. G., Murray, L. J., O\u2019Sullivan, J. M. & Powe, D. G. Beta-blocker usage and prostate cancer survival: a nested case\u2013control study in the UK clinical practice research datalink cohort. Cancer Epidemiol. 38 (3), 279\u2013285 (2014).","journal-title":"Cancer Epidemiol."},{"issue":"6","key":"37464_CR34","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ije\/dyt196","volume":"42","author":"CR Cardwell","year":"2013","unstructured":"Cardwell, C. R., Coleman, H. G., Murray, L. J., Entschladen, F. & Powe, D. G. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort. Int. J. Epidemiol. 42 (6), 1852\u20131861 (2013).","journal-title":"Int. J. Epidemiol."},{"issue":"18","key":"37464_CR35","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1016\/j.ejca.2013.07.141","volume":"49","author":"E Livingstone","year":"2013","unstructured":"Livingstone, E. et al. \u03b2-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur. J. Cancer. 49 (18), 3863\u20133871 (2013).","journal-title":"Eur. J. Cancer"},{"key":"37464_CR36","doi-asserted-by":"crossref","unstructured":"Wang, W. & Cao, X. Beta-adrenergic signaling in tumor immunology and immunotherapy. Crit. Reviews\u2122 Immunol. ;39(2). (2019).","DOI":"10.1615\/CritRevImmunol.2019031188"},{"issue":"3","key":"37464_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1006\/bbrc.1994.1359","volume":"199","author":"D Perezsala","year":"1994","unstructured":"Perezsala, D. & Mollinedo, F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199 (3), 1209\u20131215 (1994).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"37464_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1172\/JCI200519935","volume":"115","author":"L Zhuang","year":"2005","unstructured":"Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R. & Freeman, M. R. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Investig. 115 (4), 959\u2013968 (2005).","journal-title":"J. Clin. Investig."},{"issue":"5","key":"37464_CR39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.21037\/tlcr.2019.09.08","volume":"8","author":"AF Hassanabad","year":"2019","unstructured":"Hassanabad, A. F. Current perspectives on Statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Translational Lung Cancer Res. 8 (5), 692 (2019).","journal-title":"Translational Lung Cancer Res."},{"issue":"3A","key":"37464_CR40","first-page":"1817","volume":"24","author":"J J\u00e1nosi","year":"2004","unstructured":"J\u00e1nosi, J. et al. Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells. Anticancer Res. 24 (3A), 1817\u20131822 (2004).","journal-title":"Anticancer Res."},{"issue":"6","key":"37464_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1189\/jlb.69.6.959","volume":"69","author":"B Wong","year":"2001","unstructured":"Wong, B. et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol. 69 (6), 959\u2013962 (2001).","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"37464_CR42","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/01.STR.0000174289.34110.b0","volume":"36","author":"JL Mart\u00edn-Ventura","year":"2005","unstructured":"Mart\u00edn-Ventura, J. L. et al. Intensive treatment with Atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 (8), 1796\u20131800 (2005).","journal-title":"Stroke"},{"issue":"2","key":"37464_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-\u03baB pathways by diverse genetic abnormalities in multiple myeloma. Cancer cell. 12 (2), 115\u2013130 (2007).","journal-title":"Cancer cell."},{"issue":"12","key":"37464_CR44","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","volume":"20","author":"A Afzal","year":"2020","unstructured":"Afzal, A., Fiala, M. A., Gage, B. F., Wildes, T. M. & Sanfilippo, K. Statins reduce mortality in multiple myeloma: a population-based US study. Clin. Lymphoma Myeloma Leuk. 20 (12), e937\u2013e43 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"37464_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12944-023-01955-4","volume":"22","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. The association of Statin therapy and cancer: a meta-analysis. Lipids Health Dis. 22 (1), 192 (2023).","journal-title":"Lipids Health Dis."},{"key":"37464_CR46","doi-asserted-by":"crossref","unstructured":"Wong, B-S., Chiu, L-Y., Tu, D-G., Sheu, G-T. & Chan, T-T. Anticancer effects of antihypertensive L-type calcium channel blockers on chemoresistant lung cancer cells via autophagy and apoptosis. Cancer Manage. Res. :1913\u20131927. (2020).","DOI":"10.2147\/CMAR.S228718"},{"key":"37464_CR47","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1245\/s10434-021-09645-0","volume":"28","author":"A Shiozaki","year":"2021","unstructured":"Shiozaki, A. et al. Amlodipine and verapamil, voltage-gated Ca 2\u2009+\u2009channel inhibitors, suppressed the growth of gastric cancer stem cells. Ann. Surg. Oncol. 28, 5400\u20135411 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"37464_CR48","doi-asserted-by":"crossref","unstructured":"Wu, L. et al. Calcium channel blocker Nifedipine suppresses colorectal cancer progression and immune escape by preventing NFAT2 nuclear translocation. Cell. Rep. ;33(4). (2020).","DOI":"10.1016\/j.celrep.2020.108327"},{"issue":"7","key":"37464_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1593\/neo.10228","volume":"12","author":"S Meister","year":"2010","unstructured":"Meister, S. et al. Calcium channel blocker verapamil enhances reticulum stress and death induced by proteasome Inhibition in myeloma cells. Neoplasia 12 (7), 550\u2013IN3 (2010).","journal-title":"Neoplasia"},{"issue":"8","key":"37464_CR50","first-page":"3917","volume":"17","author":"H Sun","year":"2016","unstructured":"Sun, H., Zhuang, R-Y., Li, T., Zheng, Y-T. & Cai, W-M. No association between calcium channel blockers and survival in patients with cancer A systematic review and Meta-analysis. Asian Pac. J. Cancer Prev. 17 (8), 3917\u20133921 (2016).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"37464_CR51","doi-asserted-by":"publisher","first-page":"14199","DOI":"10.1038\/s41598-017-14230-1","volume":"7","author":"Y Fourbon","year":"2017","unstructured":"Fourbon, Y. et al. Ca2\u2009+\u2009protein alpha 1D of CaV1. 3 regulates intracellular calcium concentration and migration of colon cancer cells through a non-canonical activity. Sci. Rep. 7 (1), 14199 (2017).","journal-title":"Sci. Rep."},{"issue":"12","key":"37464_CR52","doi-asserted-by":"publisher","first-page":"e113649","DOI":"10.1371\/journal.pone.0113649","volume":"9","author":"D-Q Guo","year":"2014","unstructured":"Guo, D-Q., Zhang, H., Tan, S-J. & Gu, Y-C. Nifedipine promotes the proliferation and migration of breast cancer cells. PloS One. 9 (12), e113649 (2014).","journal-title":"PloS One"},{"issue":"2","key":"37464_CR53","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3892\/mmr.2017.6818","volume":"16","author":"T Zhao","year":"2017","unstructured":"Zhao, T., Guo, D., Gu, Y. & Ling, Y. Nifedipine stimulates proliferation and migration of different breast cancer cells by distinct pathways. Mol. Med. Rep. 16 (2), 2259\u20132263 (2017).","journal-title":"Mol. Med. Rep."},{"issue":"22","key":"37464_CR54","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1158\/0008-5472.CAN-08-0851","volume":"68","author":"AY Khakoo","year":"2008","unstructured":"Khakoo, A. Y., Sidman, R. L., Pasqualini, R. & Arap, W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res. 68 (22), 9112\u20139115 (2008).","journal-title":"Cancer Res."},{"issue":"2","key":"37464_CR55","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/jcp.10313","volume":"196","author":"S Greco","year":"2003","unstructured":"Greco, S. et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J. Cell. Physiol. 196 (2), 370\u2013377 (2003).","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"37464_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/JCI16645","volume":"112","author":"K Egami","year":"2003","unstructured":"Egami, K. et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Investig. 112 (1), 67\u201375 (2003).","journal-title":"J. Clin. Investig."},{"issue":"2","key":"37464_CR57","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","volume":"294","author":"M Fujita","year":"2002","unstructured":"Fujita, M., Hayashi, I., Yamashina, S., Itoman, M. & Majima, M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem. Biophys. Res. Commun. 294 (2), 441\u2013447 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"37464_CR58","doi-asserted-by":"publisher","first-page":"670657","DOI":"10.3389\/fphar.2021.670657","volume":"12","author":"Y Deng","year":"2022","unstructured":"Deng, Y. et al. Effects of antihypertensive drugs use on risk and prognosis of colorectal cancer: a meta-analysis of 37 observational studies. Front. Pharmacol. 12, 670657 (2022).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"37464_CR59","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12885-022-09513-4","volume":"22","author":"P-C Li","year":"2022","unstructured":"Li, P-C., Huang, R-Y., Yang, Y-C., Hsieh, K-P. & Yang, Y-H. Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension-a real-world study. BMC Cancer. 22 (1), 430 (2022).","journal-title":"BMC Cancer"},{"issue":"12","key":"37464_CR60","doi-asserted-by":"publisher","first-page":"18640","DOI":"10.18632\/oncotarget.15553","volume":"8","author":"R Coulson","year":"2017","unstructured":"Coulson, R. et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget 8 (12), 18640\u201318656 (2017).","journal-title":"Oncotarget"},{"key":"37464_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6242-8","volume":"19","author":"P Liu","year":"2019","unstructured":"Liu, P. et al. Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study. BMC Cancer. 19, 1\u201312 (2019).","journal-title":"BMC Cancer"},{"key":"37464_CR62","doi-asserted-by":"publisher","first-page":"609901","DOI":"10.3389\/fphar.2021.609901","volume":"12","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Association between antihypertensive medication use and breast cancer: a systematic review and meta-analysis. Front. Pharmacol. 12, 609901 (2021).","journal-title":"Front. Pharmacol."},{"issue":"14","key":"37464_CR63","doi-asserted-by":"publisher","first-page":"8373","DOI":"10.3390\/ijerph19148373","volume":"19","author":"M Na Takuathung","year":"2022","unstructured":"Na Takuathung, M. et al. Adverse effects of angiotensin-converting enzyme inhibitors in humans: a systematic review and meta-analysis of 378 randomized controlled trials. Int. J. Environ. Res. Public Health. 19 (14), 8373 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"736","key":"37464_CR64","doi-asserted-by":"publisher","first-page":"e832","DOI":"10.3399\/BJGP.2023.0153","volume":"73","author":"WN Insani","year":"2023","unstructured":"Insani, W. N. et al. Impact of aceis and ARBs-related adverse drug reaction on patients\u2019 clinical outcomes: a cohort study in UK primary care. Br. J. Gen. Pract. 73 (736), e832\u2013e42 (2023).","journal-title":"Br. J. Gen. Pract."},{"key":"37464_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-13-91","volume":"13","author":"C-H Chang","year":"2014","unstructured":"Chang, C-H. et al. Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc. Diabetol. 13, 1\u20139 (2014).","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"37464_CR66","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/S0272-6386(99)70326-4","volume":"33","author":"H Rabb","year":"1999","unstructured":"Rabb, H., Gunasekaran, H., Gunasekaran, S. & Saba, S. R. Acute renal failure from multiple myeloma precipitated by ACE inhibitors. Am. J. Kidney Dis. 33 (2), e5 (1999).","journal-title":"Am. J. Kidney Dis."},{"key":"37464_CR67","doi-asserted-by":"crossref","unstructured":"Derudas, D. & Concu, C. Management of Renal Failure in Multiple Myeloma (IntechOpen, 2022).","DOI":"10.5772\/intechopen.105444"},{"key":"37464_CR68","doi-asserted-by":"crossref","unstructured":"Mussap, M. & Merlini, G. Pathogenesis of renal failure in multiple myeloma: any role of contrast media? Biomed. Res. Int. ;2014. (2014).","DOI":"10.1155\/2014\/167125"},{"issue":"9","key":"37464_CR69","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica, D. A. Diuretic-related side effects: development and treatment. J. Clin. Hypertens. 6 (9), 532\u2013540 (2004).","journal-title":"J. Clin. Hypertens."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37464-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37464-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37464-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T22:02:42Z","timestamp":1772143362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37464-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37464"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37464-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HOA is on the advisory board of ROCHE, MSD, BMS, ASTRAZENECA, and Novartis. All other authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The secondary analysis of de-identified data reported in this study was considered negligible risk research and has been approved by the University of Sharjah Ethics Committee (Approval reference number: REC-23-11-07-01-F).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable to this independent, secondary analysis study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"7683"}}